Health News: [diabetes ]: Artificial pancreas, anyone?

Yahoo! Health   |  My alerts   |   Edit Alert Monday, Jun 24, 2013 08:11 AM EDT

Health News : diabetes - News from Yahoo !   Lexicon Presents Preclinical Data On LX2761, a New Clinical Candidate for Diabetes Designed to Reduce Glucose ... Mon, 24 Jun, 2013 05:01 AM PDT THE WOODLANDS, Texas, June 24, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, presented ... Continue reading LabStyle Innovations Names Harmonium Pharma as Exclusive Distributor for Dario in Italy Mon, 24 Jun, 2013 05:00 AM PDT LabStyle Innovations Corp. , developer of the Dario™ smartphone-based glucose monitor and diabetes data-management system, announces that Harmonium Pharma has been named as the exclusive distributor for Dario in Italy. Continue reading Global study: 1 in 4 Canadians with diabetes experience significant emotional distress, 1 in 6 report feelings of ... Mon, 24 Jun, 2013 05:00 AM PDT CHICAGO, June 24, 2013 /CNW/ - Results from the global Diabetes Attitudes, Wishes and Needs 2 study (DAWN2™) show that 28 per cent of Canadians living with diabetes have experienced significant emotional ... Continue reading Lexicon Presents Data at the American Diabetes Association Meeting On Blood Pressure Reduction and Weight Loss In ... Mon, 24 Jun, 2013 05:00 AM PDT THE WOODLANDS, Texas, June 24, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, delivered ... Continue reading

Health News : diabetes - News from other sources.   Artificial pancreas, anyone? Mon, 24 Jun, 2013 05:08 AM PDT Doctors are reporting a major step towards "artificial pancreas," a device that would constantly monitor blood sugar in people with diabetes and automatically supply insulin as needed. Continue reading Islet Sciences, Inc. Technologies Featured in Five Separate Presentations at the American Diabetes Association Annual ... Mon, 24 Jun, 2013 05:05 AM PDT NEW YORK, June 24, 2013 /PRNewswire/ -- Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announces that its technologies were featured at the American... Continue reading New GSK diabetes drug works, but faces tough competition Mon, 24 Jun, 2013 04:52 AM PDT GlaxoSmithKline's experimental once-weekly diabetes drug albiglutide was effective in late-stage clinical trials, but the medicine may struggle to differentiate itself in an increasingly competitive market. Continue reading Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment Mon, 24 Jun, 2013 04:47 AM PDT Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a new study in which linagliptin demonstrated statistically significant reductions in blood glucose levels (HbA1c) after 12 weeks (the study's primary endpoint) in adults with type 2 diabetes (T2D) with mo... Continue reading Analysts: GSK's albiglutide will face tough competition Mon, 24 Jun, 2013 04:37 AM PDT LONDON (Reuters) - GlaxoSmithKline's experimental once-weekly diabetes drug albiglutide was effective in late-stage clinical trials, but the medicine may struggle to differentiate itself in an increasingly competitive market. Albiglutide belongs to the... Continue reading Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes Mon, 24 Jun, 2013 04:33 AM PDT Sanofi US (EURONEXT: SAN and NYSE: SNY) announced today data that showed lixisenatide, an investigational once-daily prandial glucagon-like peptide 1 (GLP-1) receptor agonist, decreased HbA1c by reducing PPG (postprandial glucose) daytime exposure when added to standard of care which includes basal insulin wi... Continue reading

You received this email because you subscribed to Yahoo! Alerts. Use this link to unsubscribe from this alert. To change your communications preferences for other Yahoo! business lines, please visit your Marketing Preferences. To learn more about Yahoo!'s use of personal information, including the use of web beacons in HTML-based email, please read our Privacy Policy. Yahoo! is located at 701 First Avenue, Sunnyvale, CA 94089.